🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The growth of RPT requires a change in the training of radiopharmacists. ow.ly/BSa650SpH1G #NuclearMedicine #Theranostics #RPTherapy

Metastasis-directed therapy based on PSMA PET/CT is superior to choline-directed MDT. Learn more: ow.ly/f03y50SpH5C #NuclearMedicine #ProstateCancer #MolecularImaging Matteo Bauckneht

The linear no-threshold method is outdated. ow.ly/jA3E50SpH7x #NuclearMedicine #Cancer #RadiationSafety

RadShap: Can we identify ROIs within an image that are most predictive of patient outcomes? ow.ly/kXW150SpH8R #NuclearMedicine #AI #Radiomics Institut Curie LITO Institut Curie Irène Buvat

Is it safe? Is it effective? The answer in a study of more than 200 patients. ow.ly/JJLH50SwVrW #NuclearMedicine #ProstateCancer #RPTherapy

Do different PSMA-targeted radiopharmaceutical therapies have different dosimetry profiles? ow.ly/iNGJ50SwVuu #NuclearMedicine #ProstateCancer #RPTherapy Jeremie Calais

CMS proposes paying separately for any diagnostic radiopharmaceutical with a per day cost greater than $630 and removing their costs from the payment amounts for the #NuclearMedicine tests. Read more: ow.ly/GE7V50Sz5og. bit.ly/3S1dcFK.

Could FAP be a valid therapeutic target in glioblastoma? ow.ly/90cW50SwVAg #NuclearMedicine #Glioblastoma #Theranostics Christoph Oster Neurologie Essen

Trial protocols can now be published in JNM: ow.ly/gSXV50SBLNi. #NuclearMedicine #ProstateCancer James Buteau Michael Hofman

State of the Art: The rise of molecular image–guided robotic surgery. ow.ly/hHtv50SBLRg #MolecularImaging #NuclearMedicine #RoboticSurgery

How can we best take care of a paraplegic patient? ow.ly/BrkH50SCxWa #NuclearMedicine #ThryoidCancer #Paraplegia Joanna Klubo-Gwiezdzinska @klubo-gwiezdzinska Sriram Gubbi, MD Babak Saboury

Is Bombesin PET/CT imaging helpful in PSMA negative prostate cancer? ow.ly/QHlO50SWG5k #NuclearMedicine #ProstateCancer #MolecularImaging @DrLouiseEmmett

Forty-nine percent of #prostatecancer patients experienced changes in management based on posttreatment SPECT/CT. ow.ly/7O8N50SWGet #RPTherapy #NuclearMedicine Thomas Hope

¹⁷⁷Lu-PSMA (R)evolution in cancer care: Is it really happening? ow.ly/XPoA50SWGhH #RPTherapy #Cancer #NuclearMedicine

When mNET patients are eligible for PRRT and everolimus, PRRT should be used first in frail populations or when an objective response is needed. ow.ly/CS3x50SWGju #NETcancer #NuclearMedicine #RPTherapy

High PRRT control rate in meningiomas! A study in 42 patients: ow.ly/qJ9r50T1gMZ #NuclearMedicine #RPTherapy #Meningioma

Nearly 1,100 publications and five years later: Is FAP-targeted #theranostics really happening? ow.ly/UFAs50T4RVM #NuclearMedicine

ChatGPT for ghostwriting: good, quick…but not so great. ow.ly/fNmy50T4S2F #ChatGPT #NuclearMedicine #MedicalResearch Irène Buvat

¹⁸F-FDG PET/CT is useful in mapping out sites of disease recurrence in #BreastCancer patients with elevated CA 15-3. ow.ly/YvI950Tfn1k #NuclearMedicine #PETscan

Navigating the future of #ProstateCancer care: AI-driven imaging and #theranostics through the lens of RELAINCE. ow.ly/V46h50Tfna0 #NuclearMedicine Michael Hofman